Business Description
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : BRVRTXBDR001
Share Class Description:
BSP:VRTX34: BRDRTotal Employee Number:
6,400Compare
Compare
Traded in other countries / regions
VRTX.USA0QZU.UKVRTX34.BrazilVRTX.MexicoVX1.GermanyVRTX.Austria1VRTX.Italy IPO Date
2019-04-29Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.65 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.38 | |||||
Interest Coverage | 452.63 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 12.85 | |||||
Beneish M-Score | -2.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.5 | |||||
3-Year EBITDA Growth Rate | 3.3 | |||||
3-Year EPS without NRI Growth Rate | 7.3 | |||||
3-Year FCF Growth Rate | -6.5 | |||||
3-Year Book Growth Rate | 10.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.47 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.75 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 89.39 | |||||
9-Day RSI | 79.37 | |||||
14-Day RSI | 72.28 | |||||
3-1 Month Momentum % | -2.91 | |||||
6-1 Month Momentum % | -10.21 | |||||
12-1 Month Momentum % | -7.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.02 | |||||
Quick Ratio | 2.57 | |||||
Cash Ratio | 1.87 | |||||
Days Inventory | 344.76 | |||||
Days Sales Outstanding | 57.92 | |||||
Days Payable | 98.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.4 | |||||
Shareholder Yield % | 1.52 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 86.24 | |||||
Operating Margin % | 38.16 | |||||
Net Margin % | 35.51 | |||||
EBITDA Margin % | 43.21 | |||||
FCF Margin % | 30.21 | |||||
OCF Margin % | 34.56 | |||||
ROE % | 24.37 | |||||
ROA % | 17.51 | |||||
ROIC % | 26.68 | |||||
3-Year ROIIC % | 5.25 | |||||
ROC (Joel Greenblatt) % | 157.07 | |||||
ROCE % | 24.39 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 29.46 | |||||
Forward PE Ratio | 25.44 | |||||
PE Ratio without NRI | 26.39 | |||||
Shiller PE Ratio | 56.28 | |||||
Price-to-Owner-Earnings | 39.59 | |||||
PS Ratio | 10.46 | |||||
PB Ratio | 6.52 | |||||
Price-to-Tangible-Book | 7.07 | |||||
Price-to-Free-Cash-Flow | 34.45 | |||||
Price-to-Operating-Cash-Flow | 30.14 | |||||
EV-to-EBIT | 23.86 | |||||
EV-to-Forward-EBIT | 22.7 | |||||
EV-to-EBITDA | 22.87 | |||||
EV-to-Forward-EBITDA | 21.57 | |||||
EV-to-Revenue | 9.88 | |||||
EV-to-Forward-Revenue | 9.27 | |||||
EV-to-FCF | 32.56 | |||||
Price-to-GF-Value | 0.99 | |||||
Price-to-Projected-FCF | 2.63 | |||||
Price-to-Median-PS-Value | 0.91 | |||||
Price-to-Graham-Number | 2.88 | |||||
| Price-to-Net-Current-Asset-Value | 27.4 | |||||
| Price-to-Net-Cash | 1012 | |||||
Earnings Yield (Greenblatt) % | 4.2 | |||||
FCF Yield % | 2.94 | |||||
Forward Rate of Return (Yacktman) % | -9.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Vertex Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 65,964.341 | ||
| EPS (TTM) (R$) | 22.761 | ||
| Beta | -0.2473 | ||
| 3-Year Sharpe Ratio | 0.36 | ||
| 3-Year Sortino Ratio | 0.54 | ||
| Volatility % | 28.19 | ||
| 14-Day RSI | 72.28 | ||
| 14-Day ATR (R$) | 4.999447 | ||
| 20-Day SMA (R$) | 582.2445 | ||
| 12-1 Month Momentum % | -7.04 | ||
| 52-Week Range (R$) | 497.63 - 669.01 | ||
| Shares Outstanding (Mil) | 1,015.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vertex Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vertex Pharmaceuticals Inc Stock Events
| Event | Date | Price (R$) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 126 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 125 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 16:30 | In 35 days | ||
| Second quarter earnings results for 2026 | 2026-08-04 | In 34 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 11:20 | 579.45 (+0.00%) | ||
| Bernstein’s 42nd Annual Strategic Decisions Conference (SDC) | 2026-05-29 09:00 | 563.37 (+0.00%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-19 14:35 | 551.93 (+0.00%) | ||
| General meeting for 2026 | 2026-05-13 09:00 | 546.46 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-04 16:30 | 529.53 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-04 | 529.53 (+0.00%) |
Show
Entries
Vertex Pharmaceuticals Inc Frequently Asked Questions
What is Vertex Pharmaceuticals Inc(BSP:VRTX34)'s stock price today?
The current price of BSP:VRTX34 is R$607.20. The 52 week high of BSP:VRTX34 is R$669.01 and 52 week low is R$497.63.
When is next earnings date of Vertex Pharmaceuticals Inc(BSP:VRTX34)?
The next earnings date of Vertex Pharmaceuticals Inc(BSP:VRTX34) is 2026-08-04 Est..
Does Vertex Pharmaceuticals Inc(BSP:VRTX34) pay dividends? If so, how much?
Vertex Pharmaceuticals Inc(BSP:VRTX34) does not pay dividend.
Press Release
Articles on Vertex Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers